Editorial: New Horizons in Health-Promoting Technologies: From Development to Rational Use

This Research Topic covers 30 articles focusing on recent advancements related to the balance in innovation technology and the rational use of medicine for better decision making.

[1]  B. Wettermark,et al.  Soft regulations in pharmaceutical policy making , 2009, Applied health economics and health policy.

[2]  Steven Simoens,et al.  Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case of Olaratumab , 2019, Applied Health Economics and Health Policy.

[3]  L. Gustafsson,et al.  Policy Change and the National Essential Medicines List Development Process in Brazil between 2000 and 2014: Has the Essential Medicine Concept been Abandoned? , 2018, Basic & clinical pharmacology & toxicology.

[4]  G. Guyatt,et al.  Essential psychiatric medicines: wrong selection, high consumption and social problems , 2015, BMC Public Health.

[5]  D Ross-Degnan,et al.  Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis , 2009, The Lancet.

[6]  B. Wettermark,et al.  Did we see it Coming? An Evaluation of the Swedish Early Awareness and Alert System , 2018, Applied Health Economics and Health Policy.

[7]  A. Hartzema,et al.  Challenges facing drug utilization research in the Latin American region , 2020, Pharmacoepidemiology and drug safety.

[8]  L. Lopes,et al.  Adverse Events in Patients With Rheumatoid Arthritis and Psoriatic Arthritis Receiving Long-Term Biological Agents in a Real-Life Setting , 2019, Front. Pharmacol..

[9]  L. Lopes,et al.  Access to medicines for diabetes treatment in Brazil: evaluation of “health has no price” program , 2016, Diabetology & Metabolic Syndrome.

[10]  G. Guyatt,et al.  Patient reports of the frequency and severity of adverse reactions associated with biological agents prescribed for psoriasis in Brazil , 2014, Expert opinion on drug safety.

[11]  Karen Sarmento Costa,et al.  Indicators related to the rational use of medicines and its associated factors , 2017, Revista de saude publica.

[12]  M. Jakovljevic,et al.  Situation, Impacts, and Future Challenges of Tobacco Control Policies for Youth: An Explorative Systematic Policy Review , 2019, Front. Pharmacol..

[13]  Brian Godman,et al.  Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications , 2014, Front. Pharmacol..

[14]  José Ruben de Alcântara Bonfim,et al.  Essencialidade e racionalidade da relação nacional de medicamentos essenciais do Brasil , 2017 .

[15]  B. Wettermark,et al.  The Early Awareness and Alert System in Sweden: History and Current Status , 2017, Front. Pharmacol..

[16]  G. Guyatt,et al.  Gap Between Official Guidelines and Clinical Practice for the Treatment of Rheumatoid Arthritis in São Paulo, Brazil. , 2016, Clinical therapeutics.

[17]  L. Lopes,et al.  Long-term benzodiazepine use in patients taking antidepressants in a public health setting in Brazil: a cross-sectional study , 2018, BMJ Open.

[18]  G. Guyatt,et al.  Adherence to guidelines in the use of biological agents to treat psoriasis in Brazil , 2014, BMJ Open.

[19]  Andy Gray,et al.  Are new models needed to optimize the utilization of new medicines to sustain healthcare systems? , 2015, Expert review of clinical pharmacology.

[20]  B. Godman,et al.  Clinical Effectiveness and Safety of Analog Glargine in Type 1 Diabetes: A Systematic Review and Meta-Analysis , 2016, Diabetes Therapy.

[21]  A. Haycox,et al.  Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs , 2013, Front. Pharmacol..

[22]  B. Godman,et al.  Insulin Glargine in a Brazilian State: Should the Government Disinvest? An Assessment Based on a Systematic Review , 2014, Applied Health Economics and Health Policy.